Pharmacogenetics of P450 oxidoreductase: Implications in drug metabolism and therapy

Pharmacogenetics and Genomics

Volumn 22, Issue 11, 2012, Pages 812-819

  Hu, Lei ^a   Zhuo, Wei ^a   He, Yi Jing ^b   Zhou, Hong Hao ^a   Fan, Lan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b University of North Carolina   (United States)

Author keywords

cytochrome P450 enzymes; cytochrome P450 oxidoreductase; drug metabolism; electron donor; genetic polymorphism; pharmacogenetics

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BUFURALOL; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; DEXTROMETHORPHAN; FENTANYL; FLUTAMIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; MACROLIDE; NEUROLEPTIC AGENT; OLANZAPINE; PROTON PUMP INHIBITOR; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TACROLIMUS; UNINDEXED DRUG; ZOLMITRIPTAN;

AEROBIC METABOLISM; ANTLEY BIXLER SYNDROME; CARDIOVASCULAR DISEASE; DRUG METABOLISM; DRUG TRANSFORMATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER MICROSOME; NONHUMAN; NULL ALLELE; OXIDATION REDUCTION REACTION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

HUMANS; LIVER; METABOLIC DETOXICATION, DRUG; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84867553855     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328358d92b     Document Type: Review

References (58)

1. Chen Q, Zhang T, Wang JF, Wei DQ. Advances in human cytochrome p450 and personalized medicine. Curr Drug Metab 2011; 12: 436-444.
2. Porter TD, Coon MJ. CytochromeP-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 1991; 266: 13469-13472.
3. Hart SN, Zhong XB. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2008; 4:439-452.
4. Miller WL, Agrawal V, Sandee D, Tee MK, Huang N, Choi JH, et al. Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 2011; 336:174-179.
5. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008; 18: 11-24.
6. Vermilion JL, Ballou DP, Massey V, Coon MJ. Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P450 reductase. J Biol Chem 1981; 256:266-277.
7. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Threedimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN-and FAD-containing enzymes. Proc Natl Acad Sci USA 1997; 94:8411-8416.
8. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008; 105:1733-1738.
9. Aigrain L, Pompon D, Truan G. Role of the interface between the FMN and FAD domains in the control of redox potential and electronic transfer of NADPH-cytochrome P450 reductase. Biochem J 2011; 435: 197-206.
10. Kenaan C, Zhang H, Shea EV, Hollenberg PF. Uncovering the role of hydrophobic residues in cytochrome P450-cytochrome P450 reductase interactions. Biochemistry 2011; 50:3957-3967.
11. Gu J,Weng Y, Zhang QY, Cui H, Behr M,Wu L, et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene:impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003; 278: 25895-25901.
12. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003; 278:13480-13486.
13. Wu L, Gu J, Cui H, Zhang QY, Behr M, Fang C, et al. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 2005; 312:35-43.
14. Xue X, Gong L, Qi X,Wu Y, Xing G, Yao J, et al. Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Toxicol Lett 2011; 205: 47-54.
15. Wortham M, Czerwinski M, He L, Parkinson A, Wan YJ. Expression of constitutive androstane receptor, hepatic nuclear factor 4. alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 2007; 35:1700-1710.
16. Christensen H, Hestad AL, Molden E, Mathiesen L. CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity. Xenobiotica 2011; 41: 1-5.
17. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a chargereversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450-reductase complex. J Pharmacol Exp Ther 2011; 338:803-809.
18. Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol 2011; 82:681-691.
19. Hart SN, Li Y, Nakamoto K, Wesselman C, Zhong XB. Novel SNPs in Cytochrome P450 oxidoreductase. Drug Metab Pharmacokinet 2007; 22:322-326.
20. Miller WL, Huang N, Agrawal V, Giacomini KM. Genetic variation in human P450 oxidoreductase. Mol Cell Endocrinol 2008; 300: 180-184.
21. Gomes AM,Winter S, Klein K, Turpeinen M, Schaeffeler E, Schwab M, et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics 2009; 10:579-599.
22. Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima-Uesaka H, Sugimoto D, et al. Genetic polymorphisms and haplotypes of POR, encoding cytochrome P450 oxidoreductase, in a Japanese population. Drug Metab Pharmacokinet 2011; 26:107-116.
23. Tomkova M, Marohnic CC, Gurwitz D, Seda O, Masters BS, Martasek P. Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations. Pharmacogenomics 2012; 13:543-554.
24. Shephard EA, Phillips IR, Santisteban I, West LF, Palmer CN, Ashworth A, et al. Isolation of a human cytochrome P-450 reductase cDNA clone and localization of the corresponding gene to chromosome 7q11.2. Ann Hum Genet 1989; 53:291-301.
25. Zhao Z, Fu YX, Hewett-Emmett D, Boerwinkle E. Investigating single nucleotide polymorphism (SNP) density in the human genome and its implications for molecular evolution. Gene 2003; 312:207-221.
26. Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, Ding X, et al. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet Genomics 2009; 19:565-566.
27. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993; 12:1-51.
28. Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a Robust in vitro system. Drug Metab Dispos 2012; 40:754-760.
29. Chen X, Pan LQ, Naranmandura H, Zeng S, Chen SQ. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PLoS One 2012; 7:e38495.
30. Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 2010; 20:611-618.
31. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 2008; 18:569-576.
32. Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, et al. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 2010; 20:677-686.
33. Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 2012; 22:590-597.
34. Dobrinas M, Cornuz J, Pedrido L, Eap CB. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. Pharmacogenet Genomics 2012; 22:143-151.
35. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9:310-322.
36. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373-388.
37. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32:210-258.
38. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
39. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010; 42:268-354.
40. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41:89-295.
41. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24:1401-1403.
42. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54:33-41.
43. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72:326-332.
44. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5:54-59.
45. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR. Role of cytochrome P450 2C9 and an allelic variant in the 40-hydroxylation of (R)-and (S)-flurbiprofen. Biochem Pharmacol 1995; 49:1269-1275.
46. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of cytochrome P450 2B6 (CYP2B6. 4-YP2B6. 9) exhibit altered rates of metabolism for bupropion and efavirenz: a chargereversal mutation in the K139E variant (CYP2B6. 8) impairs formation of a functional cytochrome P450-reductase complex. J Pharmacol Exp Ther 2011; 338:803-809.
47. Degoma EM, Rivera G, Lilly SM, Usman MH, Mohler ER III. Personalized vascular medicine: individualizing drug therapy. Vasc Med 2011; 16: 391-404.
48. Zhang X, Li L, Ding X, Kaminsky LS. Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 2011; 39:1433-1439.
49. De Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase 28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011; 12:1281-1291.
50. Oneda B, Crettol S, Jaquenoud Sirot E, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 2009; 19:877-883.
51. Yang G, Fu Z, Chen X, Yuan H, Yang H, Huang Y, et al. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin Ther 2011; 33:2060-2070.
52. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 1997; 57:4830-4837.
53. Li DX, Chen SQ. Effects of genetic variations of human P450 oxidoreductase on the metabolic activation of anticancer prodrugs and environmental toxins. Doctoral Disseration 2009;1-97.
54. Bradner WT. Mitomycin C a clinical update. Cancer Treat Rev 2001; 27: 35-50.
55. Wang SL, Han JF, He XY, Wang XR, Hong JY. Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug Metab Dispos 2007; 35:176-179.
56. Pandey AV. Biochemical analysis of mutations in P450 oxidoreductase. Biochem Soc Trans 2006; 34:1186-1191.
57. Fluck CE, Nicolo C, Pandey AV. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam Clin Pharmacol 2007; 21:399-410.
58. Marohnic CC, Panda SP, Martasek P, Masters BS. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 2006; 281:35975-35982.